Use of GLP1RAs and occurrence of respiratory disorders: a meta ‐analysis of large randomized trials of GLP1RAs

ConclusionGLP1RAs show the reduced trends in the risks of 9 kinds of respiratory disorders (e.g., pneumonia, SCCL, asthma, and COPD), but the increased trend in the risk of ILD. However, these findings need to be validated by further studies due to the low incidence rates of all the respiratory disorders.

Source: The Clinical Respiratory Journal - April 7, 2021 Category: Respiratory Medicine Authors: Jin ‐Ping Wei, Chang‐Lin Yang, Wen‐Hua Leng, Liang‐Liang Ding, Guo‐Hou Zhao Tags: BRIEF REPORT Source Type: research